View : 151 Download: 11

High dose therapy followed by autologous peripheral blood stem cell transplantation as a fist line treatment for multiple myeloma: a Korean multicenter study

Title
High dose therapy followed by autologous peripheral blood stem cell transplantation as a fist line treatment for multiple myeloma: a Korean multicenter study
Authors
Bang, SMCho, EKSuh, CYoon, SSSeong, CMCho, KSKang, YGPark, SAhn, MJPark, YSOh, DKim, HCJung, CWKim, SLee, JH
Ewha Authors
성주명
SCOPUS Author ID
성주명scopus
Issue Date
2003
Journal Title
JOURNAL OF KOREAN MEDICAL SCIENCE
ISSN
1011-8934JCR Link
Citation
vol. 18, no. 5, pp. 673 - 678
Keywords
multiple myelomatransplantation autologousperipheral blood stem cell transplantation
Publisher
KOREAN ACAD MEDICAL SCIENCES
Indexed
SCI; SCIE; SCOPUS; KCI WOS scopus
Abstract
We conducted a phase II multicenter trial to estimate the response and survival of patients with newly diagnosed multiple myeloma to high dose melphalan therapy followed by autologous peripheral blood stem cell transplantation. Eligible patients who had undergone induction with vincristine, adriamycin and dexamethasone (VAD) should have adequate cardiac, pulmonary and renal function (creatinine <2 mg/dL). Melphalan at 200 mg/ml was used as a conditioning regimen. Eighty patients were enrolled from 13 centers. The median age of the patients was 53 yr (range; 20 to 68 yr). The initial stage was IA/IIA/IIB/IIIA/IIIB in 3/8/1/54/14 patients, respectively. Beta(2)-microglobulin, CRP and LDH were increased in 74, 42 and 34% of the patients examined. Cytogenetic data were available in 30 patients, and 6 patients showed numeric or structural abnormalities. Two therapy-related mortalities occurred from infection. Among the 78 evaluable patients, CR/PR/MR/NC/PD were achieved in 48/26/2/1/1 patients, respectively. After a median follow-up of 30 months, the median overall and event-free survivals were 66 months (95% CI: 20112) and 24 months (95% CI: 18-29), respectively. This study verifies the efficacy and feasibility of high dose melphalan therapy with autologous stem cell transplantation in newly diagnosed multiple myeloma.
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
High dose therapy followed by autologous peripheral blood stem cell transplantation as a fist line treatment for multiple myeloma.pdf(106.06 kB)Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE